Tevogen (TVGN) closed at $5.72 on November 10, 2026, down 2.1% from the previous close, on volume of 1,558 shares (30-day average 8,717).
Data as of November 10, 2026.
No headlines found.
Tevogen Complements Capital Access with Two-Year Extension to Loan Agreement
Globe Newswire (Mon, 9-Nov 8:05 AM ET)
UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC
Globe Newswire (Thu, 8-Oct 3:50 PM ET)
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC
Globe Newswire (Thu, 8-Oct 2:10 PM ET)
Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements
Globe Newswire (Wed, 30-Sep 4:30 PM ET)
Tevogen Inc is a healthcare enterprise engaged in biotechnology, artificial intelligence and technology, and healthcare services. Its operations focus on the development of biotechnology products, AI- and technology-based healthcare solutions, and healthcare service initiatives.
Tevogen trades on the NASDAQ stock market under the symbol TVGN.
As of November 10, 2026, TVGN stock price declined to $5.72 with 1,558 million shares trading.
TVGN has a market cap of $95.87 million. This is considered a Micro Cap stock.
The top ETF exchange traded funds that TVGN belongs to (by Net Assets): VTI, VXF.
TVGN has underperformed the market in the last year with a price return of -76.2% while the SPY ETF gained +11.2%. TVGN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -10.5% and -8.9%, respectively, while the SPY returned -2.7% and -2.6%, respectively.
TVGN support price is $5.28 and resistance is $6.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TVGN shares will trade within this expected range on the day.